ASCO: Spotlight shines on PARP inhibitors, but no star emerges

The side effects of drugs that inhibit poly ADP-ribose polymerase (PARP) are so tolerable and their activity in BRCA-positive tumors is so remarkable that cancer patients are seeking out clinical trials and clinicians are eager to enroll women with breast and ovarian cancer in the studies.